Visual subnetwork dysfunction in Parkinson’s patients with primary visual hallucinations
Objective: To evaluate impairments in the visual subnetwork in Parkinson’s disease (PD) patients with psychosis using BOLD fMRI Background: Psychosis occurs in 20-70% of patients…Use of Inappropriate Antipsychotics Among US Long-Term Care Residents with Parkinson’s Disease Psychosis
Objective: To characterize the use of inappropriate antipsychotic therapies among residents with Parkinson’s disease psychosis (PDP) in long-term care (LTC) settings in the US. Background:…Evaluating the Inappropriate Use of Antipsychotics in Parkinson’s Disease Psychosis Patients Within Large National US Healthcare Databases
Objective: To identify Parkinson’s disease psychosis (PDP) treatment characteristics from an aggregate of US national insurer and Medicare databases. Background: Treatment of psychotic symptoms associated…A life-threatening case of Anti-IgLON5 disease
Objective: To present a case of anti-IgLON5 disease with life-threatening respiratory complications. Background: Anti-IgLON5 disease is a little known CNS disorder characterized by non-REM and…The mGlu2/3 orthosteric antagonist LY-341,495 abolishes the anti-dyskinetic and anti-psychotic effects of the mGlu2 positive allosteric modulator LY-487,379 in the MPTP-lesioned marmoset
Objective: We seek to determine the effect of orthosteric blockade of metabotropic glutamate 2 and 3 (mGlu2/3) receptors with LY-341,495 on the anti-dyskinetic and anti-psychotic…LY-341,495, an mGlu2/3 antagonist, abolishes the anti-dyskinetic and anti-psychotic effects of the mGlu2/3 orthosteric agonist LY-354,740 in the MPTP-lesioned marmoset
Objective: We aim to determine the effect of orthosteric blockade of metabotropic glutamate 2 and 3 (mGlu2/3) receptors with LY-341,495 on the anti-dyskinetic and anti-psychotic…Movement Disorders Patients in Long-Term Care: Protecting Access to Appropriate Treatment
Objective: To better understand the impact of gradual dose reduction (GDR) on patients with movement disorders living in long-term care facilities (LCTFs). Background: More than…Defence Mechanism of Ego and Coping Strategy Style of the Patient with Parkinson’s Disease
Objective: To find out the prevalence of different defence mechanism and coping strategies in the patients with PD.To find out the relationship between using of…Psychosis in Prodromal Parkinson’s disease
Objective: To investigate a possible association between psychosis and prodromal Parkinson’s disease (PD) in a population-based cohort, the Hellenic Longitudinal Investigation of Aging and Diet…Apathy : Clinical Correlates in Parkinson’s disease Psychosis
Objective: To determine the frequency and clinical correlates of apathy in Parkinson’s disease (PD) psychosis. Background: The underlying pathology of apathy in PD psychosis, itself…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 13
- Next Page »